AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Bullish +75

European Commission approves AbbVie’s Aquipta for the acute treatment of migraine in adults

🏛️ The European Commission has approved AbbVie's Aquipta (atogepant) for the acute treatment of migraine in adults with or without aura.

💊 This approval marks the second indication for Aquipta in the EU, expanding its use from once-daily prevention to as-needed acute relief.

👥 The drug is indicated for both chronic and episodic migraine patients who experience four or more migraine days per month.

🗣️ Roopal Thakkar of AbbVie stated that this approval addresses unmet needs by offering a broad portfolio of acute and preventive treatments.

📉 Migraine affects approximately 14% of the global population, with a higher incidence in women and significant economic burdens.

💰 Recent analysis estimates migraine contributes between 1.2% to 2.0% of GDP in six European countries due to lost productivity.

🧠 Uwe Reuter from the European Headache Federation noted that Aquipta helps clinicians better address the socioeconomic burden of this invisible disease.

📊 The approval is supported by data from the phase 3 ECLIPSE study, which evaluated efficacy and safety versus placebo.

⚡ Aquipta demonstrated superiority to placebo in achieving pain freedom at two hours after treating the first migraine attack (p<0.0001).

🛡️ The drug showed statistical significance across secondary endpoints including reduced rescue medication use and sustained pain freedom up to 48 hours.

🩺 During the 16-week treatment period, Aquipta's safety profile was consistent with its approved preventive indication.

⚠️ The most common adverse events observed were nasopharyngitis and upper respiratory tract infection.

🌍 The ECLIPSE study enrolled 1,328 adults across 149 sites in Europe, the UK, Japan, China, South Korea, and Taiwan.

📅 Participants were randomized to treat four qualifying migraine attacks during a 16-week double-blind period followed by an open-label extension.

💊 Aquipta is administered as a single oral dose of atogepant (60 mg) taken as needed for acute treatment.

🔄 The drug functions as a calcitonin gene-related peptide (CGRP) receptor antagonist to block migraine pathways.

Bullish Signals
  • The European Commission has approved AbbVie's Aquipta (atogepant) for the acute treatment of migraine in adults, marking a significant milestone and expanding its approved indications in the European Union.
  • Clinical data from the phase 3 ECLIPSE study demonstrated that Aquipta was superior to placebo in achieving pain freedom at two hours after treatment of the first migraine attack (p<0.0001).
  • The drug showed statistical significance versus placebo across key secondary endpoints, including sustained pain freedom up to 48 hours and reduced use of rescue medication within 24 hours.
  • AbbVie now offers a broad portfolio of acute and preventive treatments for chronic and episodic migraine in Europe, addressing unmet needs for patients with four or more migraine days per month.
  • The pivotal phase 3 study enrolled 1,328 adults across 149 sites in Europe, the United Kingdom, Japan, China, South Korea, and Taiwan, providing robust data on efficacy and safety.
  • Aquipta's safety profile during the 16-week treatment period was generally consistent with its approved preventive indication, with common adverse events limited to nasopharyngitis and upper respiratory tract infection.
Risk Factors
  • The approval expands AbbVie's portfolio but does not mention any specific financial risks or market share threats associated with this new indication.
  • Safety data indicates adverse events were consistent with the preventive indication, primarily nasopharyngitis and upper respiratory tract infections, which could impact patient compliance if these side effects persist in the acute setting.
Full Analysis
The European Commission has granted approval for AbbVie's Aquipta (atogepant) to treat acute migraine attacks in adults with or without aura, marking the second indication for the drug within the European Union. This new approval expands on its existing status as a once-daily preventive treatment for adults suffering from chronic or episodic migraine who experience four or more migraine days per month. The regulatory decision is based on data from the phase 3 ECLIPSE study, which evaluated the efficacy and safety of Aquipta (60 mg) versus placebo for treating single attacks and managing multiple attacks over time. The pivotal ECLIPSE study demonstrated that Aquipta was superior to placebo in achieving pain freedom at two hours after treatment during the first migraine attack, with a p-value less than 0.0001. The study also showed statistical significance across secondary endpoints, including freedom from the most bothersome symptom at two hours, pain relief at two hours, reduced rescue medication use within 24 hours, and sustained pain freedom lasting up to 48 hours. Safety data from a 16-week placebo-controlled period indicated that adverse events were generally consistent with those observed in the drug's preventive indication, primarily consisting of nasopharyngitis and upper respiratory tract infections. The study enrolled 1,328 adults aged 18 to 75 across 149 sites in Europe, the United Kingdom, Japan, China, South Korea, and Taiwan. Participants were randomized to receive either atogepant or placebo during a 16-week double-blind period before entering an open-label extension phase. AbbVie executives highlighted that this approval addresses unmet needs for acute migraine treatment in Europe, offering patients a broad portfolio of options for both chronic and episodic conditions. The drug is administered orally as needed for acute relief and once daily for prevention, targeting the calcitonin gene-related peptide (CGRP) receptor pathway.